Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune... see more

TSX:ONC - Post Discussion

Oncolytics Biotech Inc > Novartis returns anti-PD1 to Chinese based company BeiGene
View:
Post by Noteable on Sep 19, 2023 12:06pm

Novartis returns anti-PD1 to Chinese based company BeiGene

https://www.biospace.com/article/releases/beigene-strengthens-global-portfolio-and-regains-full-rights-from-novartis-for-anti-pd-1-antibody-tevimbra-tislelizumab-/
Comment by Noteable on Sep 19, 2023 4:59pm
September 19, 2023 - The news marks the end of a second immuno-oncology partnership between the two companies after they parted ways on BeiGene’s anti-TIGIT candidate ociperlimab about two months ago. In a statement to Fierce Pharma, Novartis said a changing PD-1 inhibitor landscape led to the decision to terminate the tislelizumab agreement. [Tislelizumab (BGB-A317) is a humanized IgG4 ...more  
Comment by Noteable on Sep 19, 2023 5:06pm
“This decision will provide Novartis with greater flexibility for development of its unique, potentially transformational pipeline assets, notably in markets where there are already approved PD-1 therapies in desired indications that can support development of our novel IO combination programs.”  Maybe cash- rich Novartis is thinking of acquiring ONCYs pelareorep to be combined ...more  
Comment by Noteable on Sep 19, 2023 5:13pm
https://www.cantor.com/our-company/conferences/global-healthcare-conference-2023/
Comment by Noteable on Sep 19, 2023 8:36pm
In case anyone missed this ... [ ONCYs Bracelet-1 study demonstrated that a non-silenced Fc receptor site on a PD-1 checkpoint inhibitor like avelumab (Bavencio) for example, resulted in significantly reduced efficacy of that PD-1 checkpoint inhibitor. avelumab has a native Fc region that retains FcγR binding capability as does tislelizumab] -- https://pubmed.ncbi.nlm.nih.gov/34484871/
Comment by 13X2413 on Sep 20, 2023 9:16am
Can't they come up with something better than a fireside chat? Opening doesn't look promising. 
Comment by Lesalpes29 on Sep 20, 2023 9:23am
13x... you said not a long timo ago that you sold... Thank you to continue to post here to help the real longs here to understand the science! Euh... You can write to PanCan people too, they are lost like us! GLTAL 
Comment by 13X2413 on Sep 20, 2023 9:28am
You think I'd be posting here if I sold. Still long, that's why I'm p*ssed.  Still hoping for a miracle. 
Comment by Lesalpes29 on Sep 20, 2023 10:26am
OK, smile it will be a green day... probably!
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities